ANTİFUNGALLERİN SİSTEMİK MANTAR İNFEKSİYONLARINDA KULLANIMI VE DUYARLILIK DENEYLERİ: GENEL YÖNLENDİRME

1. Rex JH, Walsh TH, Sobel JD, Filler SG, Pappas PG,
Dismukes WE, Edwards JE. Practice guidelines for the
treatment of candidiasis. Clin Infect Dis 2000; 30: 662-
678.
2. Yücel A. Mikozların tedavisi: Antifungal ilaçlar. Yücel
A, Tabak F, Öztürk R, Mert A. (ed). Günümüzde
Antimikrobik Tedavi’de. İstanbul Bulaşıcı Hastalıklarla
Savaş Derneği Yayın no: 12. İstanbul, 1998: 117-142
2a. Bennett JL. Antifungal agents. Mandell, Douglas,
Bennett (eds). In: Principles and practise of infectious
disease. 4th ed. NewYork, Churchill Livingstone, 1995:
401-410.
2b. Patel R. Antifungal agents. Part I. Amphotericin B
preparations and flucytosine. Mayo Clin Proc 1998; 73:
1205-1225.
2c. Sheehan DJ, Hitchock A, Sibley CM. Current and
emerging azole antifungal agents. Clin Microbiol Rev
1999; 12: 40-79.
2d. Ryder NS. Activity of terbinafine against serious fungal
pathogens. Mycoses 1999 ; 42 (Suppl 2): 115-119.
2e. Richardson MD, Kokki M. Therapeutic Guidelines in
Systemic Fungal Infections. London: Current Medical
Literature Ltd, 1998.
3. Rex JH, TJ Walsh, Sobel JD, Filler SG, Pappas PG,
Dismukes WE, Edwards JE. Practice guidelines for the
treatment of candidiasis. Clin Infect Dis 2000; 30: 662-
678.
4. Edwards JR, Bodey GP, Bowden RA, Büchner T, de
Pauw BE, Filler SG, Ghannoum MG, Glauser M,
Herbrecht R, Kauffman CA, Kohno S, Martino P,
Meunier F, Mori T, Pfaller MA, Rex JH, Togers TR,
Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M.
International Conference for the development of a
consensus on the management and prevention of severe
candidal infections. CID 1997; 25: 43-59.
5. Van der Anker JN, van Popele NM, Sauer PJ. Antifungal
agents in neonatal systemic candidiasis. Antimicrob
Agents Chemother 1995; 39: 1391-1397.
6. Brammer KW, Coates PE. Pharmacokinetics of
fluconazole in pediatric patients. Eur J Clin Microbiol
Infect Dis 1994; 13: 325-329.
7. Sobel JD, Kaufman CA, McKinsey D, Zervos M,
Vazquez JA, Karchmer AW, Lee J, Thomas C, Panzer H,
Dismukes WE. Candiduria: a randomized, double-blind
study of treatment with fluconazole and placebo. Clin
Infect Dis 2000; 30: 19-24.
8. Wise GJ, Silver DA. Fungal infections of the
genitourinary system. J Urol 1993; 149: 1377-1388.
9. Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey
GP. Primary Candida pneumonia: experience at a large
cancer center and review of the literature. Medicine
(Baltimore) 1993; 72: 137-142.
10. El-Ebiary M, Torres A, Fabrega N, de la Bellacasa JP,
GonzaleZ J, Rami del Bano D, Hernandez J, Jimenez de
Anta MT. Significanse of the isolation of Candida
species from respiratory samples in critically ill, nonneutropenic
patients. Am J Respir Crit Care Med 1997;
156: 583-590.
11. Schorling SR, Kontiga HC, Froschb M, Muhlschgel FA.
The role of Candida dubliniensis in oral candidiasis in
human immunodeficiency virus-infected individuals. Crit
Rev Microbiol 2000; 26: 59-68.
12. Meiller TF, Jabra-Rizk MA, Baqui Aa, Kelley LI, Meeks
VI, Merz VG, Far VA. Oral Candida dubliniensis as a
clinically important species in HIV-seropositive patients
in the United States. Oral Surg Oral Med Oral Pathol
Oral Radiol 1999; 88: 573-580.
13. Quale J. Failure of all antifungal therapy for infection due
to Candida albicans: a new AIDS-related problem? Clin
Infect Dis 1998, 26: 183-184.
14. Quindos G, Carillo-Munoz AJ, Arevalo MP, Salgado J,
Alonso-Vargas P, Rodrigo JM, Ruesga MT, Valverde A,
Peman J, Canton E, Martin-Mazo E, Ponton J. In vitro
susceptibility of Candida dubliniensis to current and new
antifungal agents. Chemother 2000; 46: 395-401.
15. Kantarcõoğlu AS, Yücel A. The presence of fluconazoleresistant
Candida dubliniensis strains among C.albicans
isolates from immunocompromized or otherwise
debilitated HIV-negative Turkish patients. Rev Iberoam
Mycol 2002; 19: 47-51.
16. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL,
Mallegol I, Wu J. A randomized, double-blind
comparison of itraconazole oral solution and fluconazole
tablets in the treatments of esophageal candidiasis. J
Infect Dis 1997; 176: 227-232.
17. Eichel M, Just-Nubling G, Helm EB, Stille W.
Itraconazole suspension in the treatment of HIV-infected
patients with fluconazole-resistant orophageal candidiasis
and esophagitis. Mycoses 1996; 39 (Suppl 1): 102-106.
18. Kibler CC, Prentice HG. A reappraisal of current
approaches to the management of fungal infections in
neutropenic patients. Curr Op Infect Dis 1998; 11: 397-
400.
19. Richardson MD, Kokki MH. Diagnosis and prevention of
fungal infection in the immunocompromized patient.
Blood Rev 1998; 12: 241-254.
20. Ferra C, Doebbeling BN, Hollis RJ, Pfaller MA, Lee CK,
Gingrich RD. Candida tropicalis vertebral osteomyelitis:
a late sequela of fungemia. Clin Infect Dis 1994; 19: 697-
703.
21. Sugar AM, Saunders C, Diamond RD. Succesful
treatment of Candida osteomyelitis with fluconazole: a
noncomparative study of two patients. Diagn Microbiol
Infect Dis 1990; 13: 517-520.
22. Hennequin C, Bouree P, Hiesse C, Dupont B, Charpentier
B. Spondylodiskitis due to Candida albicans: report of
two patients who were succesfully treated with
fluconazole and review of literature. Clin Infect Dis
1996; 23: 176-178.
23. Scarcella A, Pasquariello MB, Giugliano B, Vendemiia
M, De Lucia A. Liposomal amphotericin B treatment for
neonatal fungal infections. Pediatr Infect Dis J 1998; 17:
146-148.
24. Stevens DA, Kan VL, Judson MA, Morrison VA,
Dummer S, Denning DW, Bennett JE, Walsh TJ,
Patterson TF, Pankey GA. Practice guidelines for
diseases caused by Aspergillus. Cin Infect Dis 2000; 30:
696-709.
25. Kantarcıoğlu A S, Yücel A, Keskinel İ, .Erk M. Bir
akciğer aspergillozu olgusunun mikoloji yönünden
izlenmesi. X. Türk Klinik Mikrobiyoloji ve İnfeksiyon
Hastalıkları Kongresi (KLİMİK), 258, Adana, 2001.
26. Kantarcıoğlu A S, Yücel A. Aspergillus cinsi mantarlar
ve invaziv aspergilloz: Mikoloji, patogenez, laboratuvar
tanımı, antifungallere direnç ve duyarlılık deneyleri. Cerr.
Tıp Derg. (Yayına kabul edilmiştir).
27. Stevens DA, Kan VL, Judson MA, Morrison VA,
Dummer S, Denning DW, Bennett JE, Walsh TJ,
Patterson TF, Pankey GA. Practice guidelines for
diseases caused by Aspergillus, Infectious Diseases
Society of America. Cin Infect Dis 2000; 30: 696-709.
28. Al-Kattan K, Ashour M, Hajjar W, Salah El Din M,
Fouda M, Al Bakry M. Surgery for pulmonary
aspergilloma in post-tuberculous vs. immunocompromised
patients. Eur J Cardiothorac Surg 2001; 20:
728-733.
29. Massard G, Roeslin N, Wihlm JM, Dumont P, Witz JP,
Morand G. Surgical treatment of pulmonary and
bronchial aspergilloma. Ann Chir 1993; 47: 147-151.
30. Kawamura S, Maesaki S, Tomono K, Tashiro T, Kohno
S. Clinical evaluation of 61 patients with pulmonary
aspergilloma. Intern Med 2000; 39: 209-212.
31. Mariotta S, Giuffredda E, Tramontano F, Treggiari S,
Ricci A, Schmid G. Therapeutic approach in pulmonary
mycetoma. Analysis of 27 patients. Panminerva Med
2001; 43: 161-165.
32. Richardson MD, Warnock DW. Fungal Infection.
Diagnosis and Management. 2nd ed. London: Blackwell
Science; 1997: 113-130.
33. Denning DW. Chronic forms of pulmonary aspergillosis.
Clin Microbiol Infect 2001; 7 (Suppl 2): 25-31.
34. Tsubura E. Multicenter clinical trial of itraconazole in the
treatment of pulmonary aspergilloma. Pulmonary
Aspergilloma Study Group. Kekkaku 1997; 72: 537-564.
35. Niwa H, Yamakawa I, Kondo K, Kiriyama M, Kondo S,
Kani H, Masaoka A. A high concentration of itraconazole
in an aspergilloma. Nşhon Kyobu Shikkan Gakkai Zasshi
1996; 34: 67-70.
36. Munk PL, Veller AD, Rankin RN, Muller NL, Ahmad D.
Intracavitary aspergilloma: transtoracic percutaneous
injection of amphotericin gelatin solution. Radiology
1993; 1888: 821-823.
37. Daly P, Kavanagh K. Pulmonary aspergillosis: clinical
presentation, diagnosis and therapy. Br J Biomed 2001;
58: 197-205.
38. Kreisel W. Therapy of invasive aspergilloasis with
itraconazole: our own experience and review of the
literature. Mycoses 1994; 42-51.
39. Bodey GP. Fungal infections in immunocompromised
patients. II. Aspergillosis and Cryptococcosis. Infect Dis
Rev 1999; 1: 87-92.
40. Hoban DJ, Zhanel GG, Karlowski JA. In vitro
susceptibilities of Candida and Cryptococcus neoformans
isolates from blood cultures of neutropenic patients.
Antimicrob Agents Chemother 1999; 43:1463-1464.
41. Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas
PG, Reingold A, Rimland D, Warnock DW. Trends in
antifungal drug susceptibility of Cryptococcus
neoformans isolates in the United States: 1992 to 1994
and 1996 to 1998. Antimicrob Agents Chemother 2001;
45: 3065-3069.
42. Van der Horst CM, Saag MS, Cloud GA, Hamill RJ,
Graybill JR, Sobel JD, Johnson PC, Tuazon CU,
Kerkering T, Moskovitz BL, Powderly WG, Dismukes
WE. Treatment of cryptococcal meningitis associated
with the acquired immunodeficiency syndrome. National
Institute of Allergy and Infectious Diseases Mycoses
Group and AI Clinical Trials Group. N Engl J Med 1997;
337: 15-21.
43. Kantarcıoğlu AS, Yücel A. Deri lezyonlardan ayrılan bir
Cryptococcus neoformans kökeni: laboratuvar tanımı,
deney farelerinde infeksiyon oluşturulması ve NCCLS
M27-A makrodilüsyon yöntemi ile yedi antifungale
duyarlılığının belirlenmesi. Cerr Tıp Derg 2001; 4: 207-
213.
44. Kantarcıoğlu AS, Mark, Viviani M, Yücel A. A
Cryptococcus neoformans (serotype A) strain isolated in
Turkey from disseminated infection in an otherwise
healty male patient. 8th Congress of the European
Confederation of Medical Mycology (Budapest, 25-27
August 2002)’ye sunulmuştur.
45. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande
MA, Gallis H, Leonard J, Fields BT, Brandshaw M,
Haywood H, McGee ZA, Cale TR, Cobbs CG, Warner
JF, Aling DW. A comparison of amphotericin B alone
and combined with flucytosine in the treatment of
cryptococcal meningitis. N Engl J Med 1979; 301: 126-
131.
46. Minamoto GY, Rosenberg AS. Fungal infections in
patients with acquired immunodeficiency syndrome. Med
Clinics North Am 1997; 81: 381-409.
47. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect
JR, Powderly WG, Sobel JD, Dismukes WE. Practice
guidelines for the management of cryptococcal disease
Infectious Diseases Society of America. Clin Infect Dis
2000; 30: 710-718.
48. Sorrell TC. Cryptococcus neoformans variety gattii. Med
Mycol 2001; 39: 155-168.
49. Coleman TK, Rogers PD, Cleary JD, Chapman SW.
Antifungal therapy during pregnancy. Cin Infect Dis
1998; 27: 1151-1160.
50. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after
first trimester vaginitis drug therapy. Obstet Gynecol
1987; 69: 751-755.
51. McNellis D, McLeod M, Lawson J, Pasquale SA.
Treatment of vulvovaginal candidiasis in pregnancy: a
comparative study. Obstet Gynecol 1977; 50: 674-678.
52. Svendsen E, Lie S, Gunderson TH, Lynsgtad-Vit I,
Skuland J. Comparative evaluation of miconazole,
clotrimazole and nystatin in the treatment of candidal
vulvo-vaginitis. Curr Ther Res 1978; 23: 666-672.
53. Tan CG, Good CS, Milne LJ, Loudon JD. A comparative
trial of six days therapy with clotrimazole and nystatin in
pregnant patients with vaginal candidiasis. Postgrad
aMed J 1974; 50 (Supll 1): 102-105.
54. Davis JE, Frudenfeld JH, Goddard JL. Comparative
evaluation of monistat and mycostatin in the treatment of
vulvo-vaginal candidiasis. Obstet Gynecol 1974; 44: 403-
406.
55. Eliot BW, Howat RC, Mack AE. A comparison between
the effects of nystatin, clotrimazole and miconazole on
vaginal candidiasis. Br J Obstet Gynecol 1979; 86: 572-
577.
56. Higton BK. A trial of clotrimazole and nistatin in vaginal
candidiasis. Postgrad Med J. 1974 50 (Suppl 1): 95-98.
57. Weisberg M. Treatment of vaginal candidiasis in
pregnant women. Clin Ther 1986; 8: 563-567.
58. Hager H, Welt SI, Cardasis JP, Alvarez S. Disseminated
blastomycosis in pregnant woman succesfully treated
with amphotericin B. J Reprod Med 1988; 33: 485-488.
59. McCoy MJ, Ellenberg JF, Killam AP.
Coccidioidomycosis complicating pregnancy. Am J
Obstet Gynecol 1966; 28: 401-405.
60. Abelcet package insert. Princeton NJ The Liposome
Company, 1996.
61. Drouhet E, Dupont B. Evaluation of antifungal agents:
past, present and future. Rev Infect Dis 1987; 9 (Suppl 1):
S4-14.
62. Lee BE, Feinberg M, Abraham JJ, Murthy ARK.
Congenital malformations in an infant born to a woman
treated with fluconazole. Pediatr Infect Dis J 1992; 11:
1062-1064.
63. Pursley TJ, Blomquist IK, Abraham J, Andersen hf,
Bartley JA. Fluconazole-induced congenital anomalies in
three infants. Clin Infect Dis 1996; 22: 336-340.
64. Aleck KA, Bartley DL. Multiple malformation syndrome
following fluconazole use in pregnancy: report of an
additional patient. Am J Med Genet 1997; 72: 253-256.
65. Tiboni GM. Second branchial arch anomalies induced by
fluconazole, a bis-triazole antifungal agent, in cultured
mouse embryos. Res Commun Chem Pathol Pharmacol
1993; 79: 381-384.
66. Inman W, Pearce GF, Wilson L. Safety of fluconazole in
the treatment of vaginal candidiass: a prescription-event
monitoring study, with special reference to outcome of
pregnancy. Eur J Clin Pharmacol 1994; 46:115-118.
67. Mastroiacovo P, Mazzone T, Botto LD. Prospective
assesment of pregnancy after first-trimester exposure to
fluconazole. Am J Obstet Gynecol 1996; 175: 1645-1650.
68. Ancobon package insert. Nutley, NJ: Roche Laboratories
1994.
69. Yücel A, Kantarcıoğlu AS. Hastane kaynaklı
(Nozokomiyal) mantar infeksiyonlarının epidemiyolojisi.
Cerr Tıp Derg 2001; 4: 259-269.
70. Schuler US, Haag C. Prophylaxis of fungal infections.
Mycoses 1997; 40 (Suppl 2): 41-44.
71. Rex JH, Sobel JD. Prophylactic antifungal therapy in the
intensive care unit. Clin Infect Dis 2001; 32: 1191- 1200.
72. Sobel JD, Rex JH. Invazive candidiasis: turning risk into
a practical prevention policy? Cin Infect Dis 2001; 33:
187-190.
73. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G,
Dunagan WC. Candidemia in a tertiary care hspital:
epidemiology, risk factors, and predictors for mortality.
Clin Infect Dis 1992; 15: 414-421.
74. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R.
Candida colonization and subsequent infections in
critically ill surgical patients. Ann Surg 1994; 220: 751-
758.
75. Munoz P, Burillo A, Bouza E. Criteria used when
initiating antifungal therapy against Candida spp. in the
intensive care unit. Int J Antimicrob Agents 2000; 15: 83-
90.
76. Singh N. Antifungal prophylaxis for solid organ
transplant recipients: seeking clarity amidst
controversery. Clin Infect Dis 2000; 31: 545-553.
77. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic
fluconazole in liver transplant recipients: a randomized,
double blind, placebo-controlled trial. Ann Intern Med
1999; 131: 729-737.
78. Lumbreras C, Cuervas-Mons V, Jara P, del Palacio A,
Turrion VS, Barri, Moreno E, Noriega AR, Paya CV.
Randomized trial of fluconazole versus nystatin for
prophylaxis of candida infection after liver
transplantation. J Infect Dis 1996; 174: 583-588.
79. Richardson MD. Antifungal therapy in “Bone marrow
failure”. Brit J Haemotol 1998; 100: 619-628.
80. Granea A, Carreras E, Rozman C, Salgado C, Sierra J,
Algara M, Rovira Valls A. Interstitial pneumonitis after
bone marrow transplantation; 15 years experience in a
single institution. Bone Marrow Transplantation 1993;
11: 453-458.
81. Yuen K-I, Woo PCY, Ip MSM et al. Stage-specific
manifestations of mold infections in bone marrow
transplant recipients: risk factors and clinical significance
of positive concentrated smears. Clin Infect Dis 1997; 25:
37-42.
82. LaRocco MT, Burgert SJ. Infection in the bone marrow
transplant recipient and role of the microbiology
laboratory in clinical transplantation. CLin Microbiol Rev
1997; 10: 277-297.
83. Richardson MD, Kokki MH. Diagnosis and prevention of
fungal infection in the immunocompromized patient.
Blood Reviews 1998; 12: 241-254.
84. Beyer J, Schwartz S et al. Strategies in prevention of
invazive pulmonary aspergillosis in immunosuppressed
or neutropenic patients. Antimicrob Agents Chemother
1994; 38: 911-917.
85. Bohme A, Just-Nubling G, Bergmann L, Shah PM, Stille
W, Hoelzer D. Itraconazole for prophylaxis of systemic
mycoses in neutropenic patients with haematological
malinnancies. J Antimicrob Chemother 1996; 38: 953-
961.
86. Todeschini G, Murari C, Bonesi R, Pizzolo G, Amaddi G,
Ambrosetti A, Piacentini I, Martini N, Montresor P. Oral
itraconazole plus nasal amphotericin B for prphylaxis of
invazive aspergillosis in patients with haematological
malignancies. Eur J Cin Microbiol Infect Dis 1993; 12:
614-618.
87. Aşçıoğlu S, De Pauw BE, Meis JFMG. Prophylaxis and
treatment of fungal infections associated with
haematological malignancies. Int J Antimicrob Agents
2000; 15: 159-168.
88. Graybill JR. Prevention of systemic mycoses in patients
who are not neutropenic: should we do it ? Can we do it?
Braz J Infect 2000; 4: 108-112.
89. De Pauw BE. Practical modalities for prevention of
fungal infections in cancer patients. Eur J Cin Infect Dis
1997; 16: 32-41.
90. Kibbler CC. Empirical antifungal therapy in febrile
neutropenic patients: current status. Curr Top Med Mycol
1997; 8: 5-14.
91. Andriole VT. Current and future therapy of invasive
fungal infections. Curr Cin Top Infect Dis 1998; 18: 19-
36.
92. Kantarcıoğlu, A. S., G. Hatemi, A. Yücel, G.S. de Hoog,
R.A. Samson ve N. M. Mendel. “Case report:
Paecilomyces variotii Bain infection of the central
nervous system in a patient with cancer”, Mycoses
(Yayına kabul edilmiştir).
93. Chandrasekar PH. Empirical antifungal therapy for
persistent fever in patients with neutropenia. Clin Infect
Dis 2001; 32: correspondance.
94. Viscoli C, Castagnola E, van Lint MT, Moroni C,
Garaventa A, Rossi M, Fanci R, Menichetti F, Caselli D,
Giacchino M, Congiu M. Fluconazole versus
amphotericin B was empirical antifungal therapy of
unexplained fever in granulocytopenic cancer patients: a
pragmatic and randomized clinical trial. Eur J Cancer
1996; 32A: 814-820.
95. Winston DJ, Hathom JW, Schuster MG, Schiller GJ,
Territo MC. A multicenter, randomized trial of
fluconazole versus amphotericin B for empiric antifungal
therapy of febrile neutropenic patients with cancer. Am J
Med 2000; 108: 282-289.
96. Donnely JP. Febrile neutropenia: antifungal prophylaxis.
Int J Antimicrob Agents 2000; 16: 127-130.
97. Pfaller MA, Rex JH, Rinaldi MG. Antifungal
susceptibility testing: Technical advances and potential
clinical applications. Clin Infect Dis 1997; 24: 776-784.
98. National Committee for Laboratory Reference Method
for Broth Dilution Antifungal Susceptibility Testing for
Yeasts. Approved Standard; Document M27-A National
Committee for Laboratory Standards.Villanova, 1997.
99. Perea S, Patterson TF. The role of antifungal
susceptibility testing in the management of patients with
invazive mycoses. Rev Iberoam Mycol 1999; 16: 180-
186.
100. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility
testing of fungi: current status of correlation of in vitro
data with clinical outcome. J Cin Microbiol 1996; 34:
489-495.
101. Espinel-Ingroff A, Barchiesi F, Hazen CK, Martinez-
Suarez V, Scalise G. Standardization of antifungal
susceptibility testing and clinical relevance. Medical
Mycology 1998; 36 (Suppl.1): 68-78.
102. Espinel-Ingroff A. Clinical utility of in vitro antifungal
susceptibility testing. Rev Esp Quimioter 2000; 13: 161-
166.
102a. Ermertcan Ş, İnci R, Hilmioğlu S, Tümbay E. Candida
kökenlerinin flukonazole in vitro duyarlılıklarının
saptanmasında makrodilüsyon ve kolorimetrik
mikrodilüsyon yöntemlerinin karşılaştırılması. İnfeksiyon
Derg 1998; 4: 525-529.
102b. Molbay D, Ener B, Gülen D, Korten V, Özek E, Bozok-
Johanson C. Çeşitli Candida kökenlerinin amfoterisin B
ve flukonazole karşı in vitro duyarlılıklarının
makrodilüsyon ve mikrodilüsyon yöntemleri ile
karşılaştırmalı olarak incelenmesi. İnfeksiyon Derg 1997;
2: 149-152.
103. Jahn B, Martin E, Stueben A, Bhakdi S. Susceptibility
testing of Candida albicans and Aspergillus species by a
simple microtiter menadione-augmented 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.
J Clin Microbiol 1995; 661-667.
104. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-
Ingrof A, Ghannoum MA, Lancaster M, Odds FC,
Rinaldi MG, Walsh TJ, Barry A. Development of
interpretive breakpoints for antifungal susceptibility
testing: conceptual framework and analysis of in vitro-in
vivo correlation data for fluconazole, itraconazole, and
Candida infections. Subcommittee on Antifungal
Susceptibility Testing of the National Committee for
Clinical Laboratory Standards. Clin Infect Dis 1997; 24:
235-247.
105. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD.
Antifungal susceptibility testing of isolates from a
randomized, multicenter trial of fluconazole versus
amphotericin B as treatment of nonneutropenic patients
with candidemia. NIAID Mycoses Study Group and the
Candidemia Study Group. Antimicrob Agents Chemother
1995; 39: 40-44.
106. Rex CH, Cooper C Jr, Merz WG, Galgiani JN, Anaissie
EJ. Detection of amphotericin B-resistant Candida
isolates in a broth-based system. Antimicrob Agents
Chemother 1995; 39: 906-909.
107. Lozano-Chiu M, Nelson PW, Lancaster M, Pfaller MA,
Rex JH. Lot to lot variability of Antibiotic Medium 3
used for testing susceptibility of Candida isolates to
Amphotericin B. J Clin Microbiol 1997; 35. 270-272.
108. Espinel-Ingroff A. Clinical relevance of antifungal
resistance. Infectious Dis Clin North America 1997; 11:
929-944.
109. Espinel-Ingroff A, Barchiesi F, Hazen KC, Martinez-
Suarez JV, Scalise G. Standardization of antifungal
susceptibility testing and clinical relevance. Med Mycol
1998; 36 (Suppl 1): 68-78.
110. Espinel-Ingroff A, Dawson K, Pfaller H Anaissie, Breslin
B, Dixon D, Fothergill A, Paetznick V, Rinaldi M.
Comparative and collaborative evaluation of
standardization antifungal susceptibility testing for
filamentous fungi.Antimicrob Agents Chemother 1995;
39: 314-319.
111. National Committee for Laboratory Standards. Reference
Method for Broth Dilution Antifungal Susceptibility
Testing of Conidium-Forming Filamentous Fungi;
Proposed Standard. Document M38-P. National
Committee for Laboratory Standards. Wayne, 1998.
112. Espinel-Ingrof A, Barttlett M, Bowden R, Chin XY,
Cooper C Jr, Fothergill A, McGinnis MR, Menezes P,
Messer SA, Nelson PW, Odds FC, Pasarell L, Peter J,
Pfaller MA, Rex JH, Rinaldi MG, Shankard GS, Walsh
TJ, Weitzman I. Multicenter evaluation of proposed
standardized procedure for antifungal susceptibility
testing of filamentous fungi. Antimicrob Agents
Chemother 1997; 35: 139-143.
113. Odds FC, Gerven FV, Espinel-Ingroff A, Bartlett MS,
Ghannoum MA, Lancaster MV, Pfaller MA, Rex JH,
Rinaldi MG, Walsh TJ. Evaluation of possible
correlations between antifungal susceptibilities of
filamentous fungi in vitro and antifungal treatment
outcomes in animal infection models. Antimicrob Agents
Chemother 1998; 42: 282-288.
114. Denning DW, Radford SA, Oakley KL, Hall L, Johnson
EM, Warnock DW. Correlation between in-vitro
susceptibility testing to itraconazole and in-vivo outcome
of Aspergillus fumigatus infection. J Antimicrob
Chemother 1997; 40: 401-414.
115. Denning DW. Therapeutic outcome in invazive
aspergillosis. Clin Infect Dis 19666; 23: 608-615.
116. Warnock DW, Johnson EM, Rogers TR. Multi-centre
evaluation of the E test method for antifungal drug
susceptibility testing of Candida spp and Cryptococcus
neoformans. BSAC Working Party on Antifungal
Chemotherapy. J Antimicrob Chemother 1998; 42: 321-
331.
117. Kantarcıoğlu AS, Yücel A. Mikrobiyoloji ve Klinik
Mikrobiyoloji Anabilim Dalı Derin Mikoz
Laboratuvarında 01 Nisan 1999- 27 Mart 2001 arasında
ayrılan maya ve küflerin tür dağõlımları ve antifungal
duyarlılık paterni. Cerr Tıp Derg 2002; 1: 7-19.
118. Kantarcıoğlu AS, Yücel A. Comparative susceptibilities
of yeast and mycelial forms of Histoplasma capsulatum
and Sporothrix schenckii strains isolated from nature to 6
antifungal agents. Abstracts of 3rd European Congress of
chemotherapy - ECC-3 (Madrid, Spain, May 7-10 2000).
Spanish Journal of Chemotherapy 2000; (Suppl 2): 31.
119. Kantarcıoğlu AS. Comparison of the ATB Fungal method
with the NCCLS broth macrodilution method (M27-A)
for determining susceptibility of Candida clinical
isolates. J Chemother 2001; 4: 446-449.
120. Withuhn F, Toubas D, Béguinot I, Aubert D, Rouger C,
Remy G, Pinon JM. Evaluation of the Fungitest Kit by
using strains from human immunodeficiency virusinfected
patients: study of azole drug susceptibility. J
Clin Microbiol 1999; 37: 864-866.
121. Swinnie D, Raes-Wuytack C, Van Looveren K, Desmet
P. Comparative evaluation of Fungitest-, Neo-Sensitabsand
M27-T- NCCLS broth microdilution methods for
antifungal drug susceptibility testing of Candida species
and Cryptococcus neoformans. Mycoses 1999; 42: 231-
237.
122. Espinel-Ingroff A, Pfaller M, Messer SA, Knapp CC,
Killian SS, Norris HA, Ghannoum MA. Multicenter
comparison of the Sensititre YeastOne Colorimetric
Antifungal Panel with the National Committee for
Clinical Laboratory Standards M27-A reference method
for testing clinical isolates of common and emerging
Candida spp, Cryptococcus spp, and other yeasts and
yeast-like organisms. J Clin Microbiol 1999; 37: 591-
595.
123. Espinel-Ingroff A, Pfaller M, Erwin ME, Jones RN.
Interlaboratory evaluation of E test method for testing
antifungal susceptibilities of pathogenic yeasts to five
antifungal agents by using Casitone agar and solidified
RPMI 1640 medium with 2% glucose. J Clin Microbiol
1996; 34: 848-852.
124. Kantarcıoğlu AS, Yücel A. Candida, Cryptococcus,
Trichosporon ve Malassezia spp kökenlerinin
antifungallere duyarlılıklarının belirlenmesinde
mikrodilüsyon ve E test yöntemlerinin referans
makrodilüsyon yöntemi ile karşılaştırılması. Türkiye
Parazitol Derg 2002; 1:.
124a. Arıkan S, Gür D, Akova M. Comparison of E test,
microdilution and colorimetric dilution with reference
broth macrodilution method for antifungal susceptibility
testing of clinically significant Candida species isolated
from immunocompromised patients. Mycoses 1997; 40:
291-296.
124b. Birinci A, Saniç A, Durupınar B, Günaydın M, Hökelek
M. Vajinal sürüntü örneklerinden izole edilen kandida
türlerinin makrodilüsyon ve E test yöntemleri ile
antifungal duyarlılıklarının araştırılması. Ankem Derg
1999; 13: 144.
125. Kantarcıoğlu AS. Sistemik mikozlularla, genel hasta
gruplarından ve doğadan ayırıp tanımladığımız
mantarların antifungallere duyarlılıklarının
karşılaştırılması. Doktora Tezi. Marmara Üniversitesi Fen
Bilimleri Enstitüsü Biyoloji Anabilim Dalı, İstanbul
2001, 462 s.
126. Yücel A, Kantarcıoğlu AS. Bir kısım dematiaceous küf
mantarlarının amfoterisin B, flukonazol, itrakonazol,
ketokonazol, mikonazol ve 5-florositozin’e in vitro
duyarlılıklarının araştırılması. İnfeksiyon Derg, 2001; 2:
215-220.
127. Yücel A, Kantarcıoğlu AS. Mantarlarda dimorfizm.
İnfeksiyon Derg, 2000; 4: 569-578.
128. British Society for Antimicrobial Chemotherapy Working
Party. Management of deep Candida infection in surgical
and intensive care unit patients. Intensive Care Med
1994; 20. 522-528.
129. Working Party of the British Society for Antimicrobial
Chemotherapy. Therapy of deep fungal infection in
haematological malignancy. J Antimicrob Chemother
1997; 40: 779-788.
130. Edwards JE Jr, Bodey GP, Bowden RA, Buchnet T, de
Pauw BE, Filler G, Ghannoum MA, Glauser M,
Herbrecht R, Kauffman CA, Kohno S, Mart P, Meunier
F, Mori T, Pfaller MA, Rex JH, Tubin RH, Solon J,
Viscoli C, Walsh TJ, White M. International conference
for the development of a concensus on the management
and prevention of severe candidal infections. Clin Infect
Dis 1997; 25: 43-59.
131. De Pauw B E. Practical Modalities for prevention of
fungal infections in cancer patients. Eur J Clin Microbiol
Infect Dis 1997; 16: 32-41.
132. Lortholary O, Dupont M. Antifungal prophylaxis
during neutropenia and immunodefficiency. Cin
Microbiol Rev 1997; 10: 477-504